Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
* Inclusion Criteria of study population Ⅰ:~  1. 18 to 65 years old;~ 2. Consent and signed informed consent forms(ICF);~ 3. Comply with follow-up;~ 4. No history of tuberculosis;~ 5. Physical condition : No obvious heart, liver, kidney, gastrointestinal tract, nervous system, mental disorder and metabolic abnormalities and other medical history from signed informed consent to the injection within four weeks prior to delivery ;by the comprehensive physical examination showed electrocardiogram, blood pressure, heart rate, breathing and laboratory tests, including blood, urine routine, liver, kidney and other various biochemical test all without exception or slightly unusual but does not affect our research;~ 6. Normal axillary temperature(quiet condition ≤37.0 ℃).~* Inclusion Criteria of study population Ⅱ:~  1. healthy people conforming to the study population Ⅰ criteria ;~ 2. the result of three detection methods( ESAT6-CFP10 (5 μg/ml or 10 μg/ml)、 TB - PPD and specific gamma - IFN ) are all the negative ;~ 3. Comply with two criteria the above (1) (2) , HIV negative, X-ray chest radiograph no abnormalities.~Exclusion Criteria of study population Ⅰand study population Ⅱ:~1. Has the following serious disease, such as advanced cancer, diabetes, chronic obstructive pulmonary disease (copd) in acute episodes, acute/ progressive liver disease or kidney disease, congestive heart failure, etc;~2. Have epilepsy, brain and nervous system symptoms or signs of history or have risk tendency of epilepsy, brain and other nervous system disease and not easy to control;~3. Has known or suspected (or risk possible) immune damaged or abnormal functional , accept glucocorticoid and immunosuppressants or immunopotentiator treatment, outside the gastrointestinal tract protein or blood products or plasma extraction in 3 months, immunodeficiency virus infection or related diseases or long-term use of antibiotics;~4. Has acute febrile diseases and infectious diseases;~5. taking part in any other new drug clinical trials or participated in any other new drug clinical trials within 3 months before this trials;~6. allergy to drugs 、alcohol 、 vaccine、drugs using in this experiment and allergic or scar constitution;~7. In pregnancy or lactation;~8. With mental or physical disabilities;~9. Researchers consider that any conditions may affect the trial evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 5μg/ml ESAT6-CFP10 after BCG immunization (Type: EXPERIMENTAL): A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
- 10μg/ml ESAT6-CFP10 after BCG immunization (Type: EXPERIMENTAL): A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
- 5μg/ml ESAT6-CFP10 after placebo immunization (Type: PLACEBO_COMPARATOR): A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
- 10μg/ml ESAT6-CFP10 after placebo immunization (Type: PLACEBO_COMPARATOR): A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete